Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus: Results of a Pooled Subgroup Analysis from Three Randomized, Controlled, Double-Blind Trials

By Jones Peter H.  

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 2, 2010-04 ,pp. : 73-84

Adis International

Access to resources Recommend Favorite

A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors

By Monk J.  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1676-1683

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia – A Phase 3 Study

By Roth Eli   Rosenson Robert   Carlson Dawn   Fukumoto Sandra   Setze Carolyn   Blasetto James   Khurmi Nardev   Stolzenbach James   Williams Laura  

Cardiovascular Drugs and Therapy, Vol. 24, Iss. 5-6, 2010-12 ,pp. : 421-428

Springer Publishing Company

Access to resources Recommend Favorite

Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination: A Phase 3, Open-Label, Extension Study

By Kipnes Mark S.  

Clinical Drug Investigation, Vol. 30, Iss. 1, 2010-01 ,pp. : 51-61

Adis International

Access to resources Recommend Favorite

Toxicity of 50-nm polystyrene particles co-administered to mice with acetaminophen, 5-aminosalicylic acid or tetracycline

By  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 69, Iss. 9, 2014-09 ,pp. : 676-679

Govi-Verlag

Access to resources Recommend Favorite